News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avexa Limited (AVX.AX) Collaborates With TargetDrug on HCV Program


6/4/2008 8:42:27 AM

MELBOURNE, Australia--(BUSINESS WIRE)--Australian biotechnology company Avexa Ltd (ASX:AVX) announced today that it will collaborate with TargetDrug on its Hepatitis C virus (HCV) program. The focus will be on the development of novel lead inhibitors of HCV replication. The Company also provided an update on the progress of its Apricitabine (ATC) Phase III trials.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES